Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vinorelbine - Pierre Fabre

Next Previous
X
Search
Drug Profile

Vinorelbine - Pierre Fabre

Alternative Names: KW-2307; Navelbine; NVB; Vinorelbine ditartrate; Vinorelbine tartrate

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CNRS
  • Developer Amgen; Bristol-Myers Squibb; Centre Oscar Lambret; Pierre Fabre; UNICANCER; University of Washington
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer
  • Phase II Glioma; Malignant-mesothelioma
  • Phase I/II Solid tumours
  • No development reported Cervical cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 23 Feb 2022 Pierre Fabre completes a Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Recurrent) in France (IV) (NCT03801304)
  • 16 Sep 2021 Adverse events and efficacy data from a phase II trial in Breast cancer released at the 46th European Society for Medical Oncology Congress (ESMO-2021)
  • 16 Sep 2021 Efficacy and adverse events data from a phase I/II MOVIE trial in Solid tumours presented at the 46th European Society for Medical Oncology Congress (ESMO-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top